Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy November 18, 2026
PIVOT-006 Ph 3 Registrational Trial shows RFS Improvement in Intermediate-Risk and High-Grade Ta NMIBC November 18, 2026
68% high-grade RFS reported at 12 months in BCG-unresponsive NMIBC study of HIVEC® with mitomycin C November 18, 2026
Positive Preliminary Ph 2 Topline Results Reported from the PIK-201 Trial of PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer November 18, 2026
ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve NMIBC Randomized QUILT-2.005 Trial November 18, 2026
Positive Updated Silevertinib Ph 2 Results Announced with FDA Feedback for Potential Registration path in 1L EGFR-NCM NSCLC November 18, 2026
Quality of Life and Pain Outcomes Data from Ph 3 PANOVA-3 Trial of Tumor Treating Fields for Pancreatic Cancer Published November 18, 2026
Updated interim results from U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent GBM announced November 18, 2026
Updated Clinical Data of Zocilurtatug Pelitecan (Zoci) in Previously Treated Extrapulmonary Neuroendocrine Carcinomas Presented November 11, 2026
Preliminary Findings from the Investigator-Sponsored Ph 2a PICASSO Trial in Metastatic Melanoma Announced November 11, 2026
Incremental Data and Analyses from Ph 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs Presented November 11, 2026
Ph 2a PICASSO Trial of MaaT013 (Xervyteg®) + immune checkpoint inhibitors in selected melanoma patients met primary endpoint November 11, 2026
Positive QoL Data for LYMPHIR® (denileukin diftitox-cxdl) in R/R Cutaneous T-Cell Lymphoma Presented November 11, 2026
Ph 2 Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine November 11, 2026
Subcutaneous RYBREVANT (amivantamab) demonstrates 77% ORR in 1L treatment of patients with certain types of advanced head and neck cancer November 4, 2026
Updated data announced from Cohort 4 of Ph 1/2 GOBLET study of pelareorep + Tecentriq in 2L+ SCAC patients November 4, 2026
Ph 3 LiGeR-HN1 trial of Petosemtamab + pembrolizumab versus pembrolizumab alone met both primary endpoints in PD-L1 positive HNSCC patients November 4, 2026
Positive Results from Ph 2 BELLA Trial of Lifyorli, Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer Reported November 4, 2026
Statistically Significant OS/ORR Improvements reported with Petosemtamab Combo at First Interim Analysis in 1L R/M Patients with PD-L1+ Head and Neck Cancer November 4, 2026
Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer November 4, 2026
ELREXFIO demonstrated clinically meaningful & statistically significant PFS benefit for RRMM patients in Ph 3 MagnetisMM-32 trial November 4, 2026
Updated results from Cohorts 1 and 2 of Ph 2 IOV-LUN-202 trial in previously treated non-squamous mNSCLC announced November 4, 2026
Additional Positive Results of Combi-TED Ph 2 Trial with Tedopi® (OSE2101) in metastatic NSCLC Announced November 4, 2026
Results from UNICORN Ph 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer Published in Nature Medicine November 4, 2026
Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in PFS and OS in Patients with Platinum-Resistant Ovarian Cancer October 27, 2026